Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
1.
Mol Cell Proteomics ; 22(9): 100632, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37586548

RESUMO

Myeloid-derived suppressor cells (MDSC) are a heterogeneous cell population of incompletely differentiated immune cells. They are known to suppress T cell activity and are implicated in multiple chronic diseases, which make them an attractive cell population for drug discovery. Here, we characterized the baseline proteomes and phospho-proteomes of mouse MDSC differentiated from a progenitor cell line to a depth of 7000 proteins and phosphorylation sites. We also validated the cellular system for drug discovery by recapitulating and identifying known and novel molecular responses to the well-studied MDSC drugs entinostat and mocetinostat. We established a high-throughput drug screening platform using a MDSC/T cell coculture system and assessed the effects of ∼21,000 small molecule compounds on T cell proliferation and IFN-γ secretion to identify novel MDSC modulator. The most promising candidates were validated in a human MDSC system, and subsequent proteomic experiments showed significant upregulation of several proteins associated with the reduction of reactive oxygen species (ROS). Proteome-wide solvent-induced protein stability assays identified Acyp1 and Cd74 as potential targets, and the ROS-reducing drug phenotype was validated by measuring ROS levels in cells in response to compound, suggesting a potential mode of action. We anticipate that the data and chemical tools developed in this study will be valuable for further research on MDSC and related drug discovery.


Assuntos
Células Supressoras Mieloides , Camundongos , Humanos , Animais , Células Supressoras Mieloides/metabolismo , Ensaios de Triagem em Larga Escala , Proteoma/metabolismo , Proteômica , Espécies Reativas de Oxigênio/metabolismo
2.
Trends Genet ; 29(7): 427-37, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23453622

RESUMO

Cell-cell fusion in sexually reproducing organisms is a mechanism to merge gamete genomes and, in multicellular organisms, it is a strategy to sculpt organs, such as muscle, bone, and placenta. Moreover, this mechanism has been implicated in pathological conditions, such as infection and cancer. Studies of genetic model organisms have uncovered a unifying principle: cell fusion is a genetically programmed process. This process can be divided in three stages: competence (cell induction and differentiation); commitment (cell determination, migration, and adhesion); and cell fusion (membrane merging and cytoplasmic mixing). Recent work has led to the discovery of fusogens, which are cell fusion proteins that are necessary and sufficient to fuse cell membranes. Two unrelated families of fusogens have been discovered, one in mouse placenta and one in Caenorhabditis elegans (syncytins and F proteins, respectively). Current research aims to identify new fusogens and determine the mechanisms by which they merge membranes.


Assuntos
Fusão Celular , Animais , Caenorhabditis elegans/fisiologia , Diferenciação Celular/fisiologia , Membrana Celular/fisiologia , Citoplasma/fisiologia , Feminino , Fertilização/genética , Fertilização/fisiologia , Regulação da Expressão Gênica no Desenvolvimento , Células Germinativas/fisiologia , Humanos , Macrófagos/fisiologia , Fusão de Membrana/genética , Fusão de Membrana/fisiologia , Camundongos , Mioblastos/fisiologia , Neurospora crassa/fisiologia , Placenta/fisiologia , Plantas/metabolismo , Gravidez , Saccharomyces cerevisiae/fisiologia
3.
Blood ; 121(9): e57-69, 2013 Feb 28.
Artigo em Inglês | MEDLINE | ID: mdl-23293084

RESUMO

The molecular repertoire of macrophages in health and disease can provide novel biomarkers for diagnosis, prognosis, and treatment. Th2-IL-4­activated macrophages (M2) have been associated with important diseases in mice, yet no specific markers are available for their detection in human tissues. Although mouse models are widely used for macrophage research, translation to the human can be problematic and the human macrophage system remains poorly described. In the present study, we analyzed and compared the transcriptome and proteome of human and murine macrophages under resting conditions (M0) and after IL-4 activation (M2). We provide a resource for tools enabling macrophage detection in human tissues by identifying a set of 87 macrophage-related genes. Furthermore, we extend current understanding of M2 activation in different species and identify Transglutaminase 2 as a conserved M2 marker that is highly expressed by human macrophages and monocytes in the prototypic Th2 pathology asthma.


Assuntos
Interleucina-4/farmacologia , Ativação de Macrófagos/genética , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Transcriptoma , Animais , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Análise por Conglomerados , Perfilação da Expressão Gênica , Humanos , Ativação de Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Macrófagos/fisiologia , Camundongos , Camundongos Endogâmicos C57BL , Modelos Biológicos , Proteoma/análise , Proteoma/efeitos dos fármacos , Especificidade da Espécie
4.
Circ Res ; 111(5): 575-84, 2012 Aug 17.
Artigo em Inglês | MEDLINE | ID: mdl-22753077

RESUMO

RATIONALE: Fetuin-A is a liver-derived plasma protein involved in the regulation of calcified matrix metabolism. Biochemical studies showed that fetuin-A is essential for the formation of protein-mineral complexes, called calciprotein particles (CPPs). CPPs must be cleared from circulation to prevent local deposition and pathological calcification. OBJECTIVE: We studied CPP clearance in mice and in cell culture to identify the tissues, cells, and receptors involved in the clearance. METHODS AND RESULTS: In mice, fetuin-A-containing CPPs were rapidly cleared by the reticuloendothelial system, namely Kupffer cells of the liver and marginal zone macrophages of the spleen. Macrophages from scavenger receptor-AI/II (SR-A)-deficient mice cleared CPPs less efficiently than macrophages from wild-type mice, suggesting that SR-AI/II is involved in CPP binding and endocytosis. Accordingly, we found reduced clearance of CPPs in SR-A/MARCO-deficient mice. CONCLUSIONS: We could demonstrate that fetuin-A-containing CPPs facilitate the clearance of mineral debris by macrophages via SR-A. Since the same receptor also contributes to the uptake of modified low-density lipoprotein particles in atherosclerosis, defective endocytosis of both types of particle may impinge on lipid as well as mineral debris clearance in calcifying atherosclerosis.


Assuntos
Aterosclerose/metabolismo , Cálcio/sangue , Células de Kupffer/metabolismo , Macrófagos/metabolismo , Receptores Imunológicos/metabolismo , alfa-2-Glicoproteína-HS/metabolismo , Animais , Apolipoproteínas E/genética , Aterosclerose/patologia , Calcificação Fisiológica/fisiologia , Calcinose/metabolismo , Calcinose/patologia , Proteínas de Ligação ao Cálcio/metabolismo , Artérias Carótidas/citologia , Bovinos , Linhagem Celular , Endocitose/fisiologia , Células de Kupffer/citologia , Lipoproteínas LDL/metabolismo , Macrófagos/citologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Sistema Fagocitário Mononuclear/metabolismo , Fosfatos/sangue , Receptores Imunológicos/genética , Receptores Depuradores Classe A/genética , Receptores Depuradores Classe A/metabolismo , Baço/citologia , alfa-2-Glicoproteína-HS/genética , alfa-2-Glicoproteína-HS/farmacologia
5.
Cancer Treat Res Commun ; 39: 100805, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38492435

RESUMO

BACKGROUND: Targeting the costimulatory receptor CD137 has shown promise as a therapeutic approach for cancer immunotherapy, resulting in anti-tumor efficacy demonstrated in clinical trials. However, the initial CD137 agonistic antibodies, urelumab and utomilumab, faced challenges in clinical trials due to the liver toxicity or lack of efficacy, respectively. Concurrently, c-MET has been identified as a highly expressed tumor-associated antigen (TAA) in various solid and soft tumors. METHODS: In this study, we aimed to develop a bispecific antibody (BsAb) that targets both c-MET and CD137, optimizing the BsAb format and CD137 binder for efficient delivery of the CD137 agonist to the tumor microenvironment (TME). We employed a monovalent c-MET motif and a trimeric CD137 Variable Heavy domain of Heavy chain (VHH) for the BsAb design. RESULTS: Our results demonstrate that the c-MET x CD137 BsAb provides co-stimulation to T cells through cross-linking by c-MET-expressing tumor cells. Functional immune assays confirmed the enhanced efficacy and potency of the c-MET x CD137 BsAb, as indicated by activation of CD137 signaling, target cell killing, and cytokine release in various tumor cell lines. Furthermore, the combination of c-MET x CD137 BsAb with Pembrolizumab showed a dose-dependent enhancement of target-induced T cell cytokine release. CONCLUSION: Overall, the c-MET x CD137 BsAb exhibits a promising developability profile as a tumor-targeted immune agonist by minimizing off-target effects while effectively delivering immune agonism. It has the potential to overcome resistance to anti-PD-(L)1 therapies.


Assuntos
Anticorpos Biespecíficos , Imunoterapia , Proteínas Proto-Oncogênicas c-met , Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral , Animais , Humanos , Camundongos , Anticorpos Biespecíficos/farmacologia , Anticorpos Biespecíficos/uso terapêutico , Linhagem Celular Tumoral , Imunoterapia/métodos , Neoplasias/tratamento farmacológico , Neoplasias/imunologia , Neoplasias/terapia , Proteínas Proto-Oncogênicas c-met/imunologia , Microambiente Tumoral/imunologia , Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral/agonistas , Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral/imunologia
6.
Cancer Immunol Res ; 12(2): 195-213, 2024 02 02.
Artigo em Inglês | MEDLINE | ID: mdl-38091375

RESUMO

The costimulatory receptor CD137 (also known as TNFRSF9 or 4-1BB) sustains effective cytotoxic T-cell responses. Agonistic anti-CD137 cancer immunotherapies are being investigated in clinical trials. Development of the first-generation CD137-agonist monotherapies utomilumab and urelumab was unsuccessful due to low antitumor efficacy mediated by the epitope recognized on CD137 or hepatotoxicity mediated by Fcγ receptors (FcγR) ligand-dependent CD137 activation, respectively. M9657 was engineered as a tetravalent bispecific antibody (mAb2) in a human IgG1 backbone with LALA mutations to reduce binding to FCγRs. Here, we report that M9657 selectively binds to mesothelin (MSLN) and CD137 with similar affinity in humans and cynomolgus monkeys. In a cellular functional assay, M9657 enhanced CD8+ T cell-mediated cytotoxicity and cytokine release in the presence of tumor cells, which was dependent on both MSLN expression and T-cell receptor/CD3 activation. Both FS122m, a murine surrogate with the same protein structure as M9657, and chimeric M9657, a modified M9657 antibody with the Fab portion replaced with an anti-murine MSLN motif, demonstrated in vivo antitumor efficacy against various tumors in wild-type and human CD137 knock-in mice, and this was accompanied by activated CD8+ T-cell infiltration in the tumor microenvironment. The antitumor immunity of M9657 and FS122m depended on MSLN expression density and the mAb2 structure. Compared with 3H3, a murine surrogate of urelumab, FS122m and chimeric M9657 displayed significantly lower on-target/off-tumor toxicity. Taken together, M9657 exhibits a promising profile for development as a tumor-targeting immune agonist with potent anticancer activity without systemic immune activation and associated hepatotoxicity.


Assuntos
Doença Hepática Induzida por Substâncias e Drogas , Neoplasias , Humanos , Animais , Camundongos , Mesotelina , Inflamação , Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral , Microambiente Tumoral
7.
FASEB J ; 21(12): 3208-18, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17551101

RESUMO

We have previously reported that 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) can selectively suppress key functions of interferon-gamma (IFN-gamma) activated macrophages. To further explore this mechanism for its relevance in vivo, we investigated an infection model that crucially depends on the function of IFN-gamma activated macrophages, the infection with the intracellular protozoan Leishmania major. 1Alpha,25(OH)2D3 treatment of L. major infected macrophages demonstrated a vitamin D receptor (Vdr) dependent inhibition of macrophage killing activity. Further analysis showed that this was a result of decreased production of nitric oxide by 1alpha,25(OH)2D3-treated macrophages due to Vdr-dependent up-regulation of arginase 1 expression, which overrides NO production by Nos2. When analyzing the course of infection in vivo, we found that Vdr-knockout (Vdr-KO) mice were more resistant to L. major infection than their wild-type littermates. This result is in agreement with an inhibitory influence of 1alpha,25(OH)2D3 on the macrophage mediated host defense. Further investigation showed that Vdr-KO mice developed an unaltered T helper cell type 1 (Th1) response on infection as indicated by normal production of IFN-gamma by CD4+ and CD8+ T cells. Therefore, we propose that the absence of 1alpha,25(OH)2D3-mediated inhibition of macrophage microbicidal activity in Vdr-KO mice results in increased resistance to Leishmania infection.


Assuntos
Leishmania major/imunologia , Leishmaniose Cutânea/imunologia , Receptores de Calcitriol/metabolismo , Transdução de Sinais/fisiologia , Animais , Arginase/metabolismo , Calcitriol/metabolismo , Citocinas/imunologia , Suscetibilidade a Doenças , Humanos , Interferon gama/metabolismo , Leishmania major/patogenicidade , Macrófagos/citologia , Macrófagos/imunologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Óxido Nítrico/metabolismo , Óxido Nítrico Sintase Tipo II/genética , Óxido Nítrico Sintase Tipo II/metabolismo , Fagocitose , Receptores de Calcitriol/genética , Linfócitos T/metabolismo
8.
Sci Rep ; 8(1): 13399, 2018 09 07.
Artigo em Inglês | MEDLINE | ID: mdl-30194424

RESUMO

The suppressive microenvironment of tumors remains one of the limiting factors for immunotherapies. In tumors, the function of effector T cells can be inhibited by cancer cells as well as myeloid cells including tumor associated macrophages and myeloid-derived suppressor cells (MDSC). A better understanding of how myeloid cells inhibit T cell function will guide the design of therapeutic strategies to increase anti-tumor responses. We have previously reported the in vitro differentiation of MDSC from immortalized mouse hematopoietic progenitors and characterized the impact of retinoic acid and 3-deazaneplanocin A on MDSC development and function. We describe here the effect of these compounds on MDSC transcriptome and identify genes and pathway affected by the treatment. In order to accelerate the investigation of gene function in MDSC suppressive activity, we developed protocols for CRISPR/Cas9-mediated gene editing in MDSC. Through screening of 217 genes, we found that autocrine secretion of TNF-α contributes to MDSC immunosuppressive activity through up-regulation of Nos2. The approach described here affords the investigation of gene function in myeloid cells such as MDSC with unprecedented ease and throughput.


Assuntos
Comunicação Autócrina , Edição de Genes/métodos , Células Supressoras Mieloides/metabolismo , Óxido Nítrico Sintase Tipo II/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Animais , Sistemas CRISPR-Cas , Células Cultivadas , Edição de Genes/normas , Camundongos , Camundongos Endogâmicos C57BL , Óxido Nítrico Sintase Tipo II/genética , Transcriptoma , Regulação para Cima
9.
Sci Rep ; 8(1): 5975, 2018 04 13.
Artigo em Inglês | MEDLINE | ID: mdl-29654304

RESUMO

By N-ethyl-N-nitrosourea (ENU) mutagenesis, we generated the mutant mouse line TUB6 that is characterised by severe combined immunodeficiency (SCID) and systemic sterile autoinflammation in homozygotes, and a selective T cell defect in heterozygotes. The causative missense point mutation results in the single amino acid exchange G170W in multicatalytic endopeptidase complex subunit-1 (MECL-1), the ß2i-subunit of the immuno- and thymoproteasome. Yeast mutagenesis and crystallographic data suggest that the severe TUB6-phenotype compared to the MECL-1 knockout mouse is caused by structural changes in the C-terminal appendage of ß2i that prevent the biogenesis of immuno- and thymoproteasomes. Proteasomes are essential for cell survival, and defective proteasome assembly causes selective death of cells expressing the mutant MECL-1, leading to the severe immunological phenotype. In contrast to the immunosubunits ß1i (LMP2) and ß5i (LMP7), mutations in the gene encoding MECL-1 have not yet been assigned to human disorders. The TUB6 mutant mouse line exemplifies the involvement of MECL-1 in immunopathogenesis and provides the first mouse model for primary immuno- and thymoproteasome-associated immunodeficiency that may also be relevant in humans.


Assuntos
Complexo de Endopeptidases do Proteassoma/imunologia , Animais , Sobrevivência Celular/imunologia , Feminino , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos SCID , Subunidades Proteicas/imunologia
10.
Immunobiology ; 212(9-10): 785-93, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-18086379

RESUMO

Multinucleated giant cells (MGCs), characteristic of granulomatous infections as well as multinucleated osteoclasts originate from fusion of macrophages. While intracellular and viral membrane fusion have been studied in detail, much less is known about the machinery which mediates cell-to-cell fusion, in particular macrophage polykaryon formation. Several molecules have been implicated in this process which may involve the action of multiple glycoproteins mediating membrane attachment and fusion. Macrophage fusion can be induced by soluble mediators such as cytokines and growth factors, even though several other stimuli may be involved, especially for the induction of granuloma-associated giant cells. The function of MGCs during granulomatous diseases is currently unknown. However, a better understanding of the mechanistic basis of macrophage fusion may lead to a better understanding of the function of MGCs found in granulomas.


Assuntos
Fusão Celular , Células Gigantes/fisiologia , Macrófagos/fisiologia , Proteínas ADAM/metabolismo , Animais , Moléculas de Adesão Celular/metabolismo , Proteína-1 Reguladora de Fusão/metabolismo , Glicosilação , Granuloma/fisiopatologia , Humanos , Interleucina-4/metabolismo , Proteínas de Membrana/metabolismo , Osteoclastos/fisiologia , Receptores de Quimiocinas/metabolismo , Receptores Purinérgicos P2/metabolismo , Receptores Purinérgicos P2X7
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA